Kala Pharmaceuticals

Kala Pharmaceuticals completed a registered direct placement of approximately $10 million, in which 10 million common shares (or pre-funded warrants) were sold at $1.00 each as part of an "at-the-market" offering. H.C. Wainwright & Co. acted as sole placement agent. Kala intends to use the net proceeds to repay existing indebtedness and for general corporate purposes; the dilution contributed to a share price decline of about 6.7%. » Plus sur de.investing.com

Kala Bio is selling 10 million common shares at $1.00 each in a registered direct placement and expects to close around December 5, 2025. The gross proceeds of about $10 million are to be used to repay certain obligations and for general corporate purposes; H.C. Wainwright & Co. is the exclusive placement agent. In parallel, a $6 million purchase agreement was made with new CEO and investor David E. Lazar (about $1.8 million received so far). Kala Bio is under financial pressure (current ratio 0.75, EBITDA -$41.31 million) and has received a termination notice from Oxford Finance on a $29.1 million loan. The phase 2b study of KPI-012 missed its primary endpoint, after which the company halted development of the program. » Plus sur de.investing.com

KALA BIO shares jumped 28.3% in premarket trading after a $6 million securities investment was agreed with private investor David E. Lazar. $1.8 million was paid at the first closing, Lazar was immediately named CEO and chairman, while Todd Bazemore remains on the board. KALA plans to use the funds to continue evaluating and developing its therapy candidates and to explore strategic options; a second closing of $4.2 million is conditional on shareholder approval in Q1 2026. The move follows the suspension of development of KPI-012 after the Phase 2b study missed its primary endpoint. » Plus sur de.investing.com